How to buy Dicerna Pharmaceuticals stock | 22.6

Dicerna Pharmaceuticals, Inc is a biotechnology business based in the US. Dicerna Pharmaceuticals shares (DRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Dicerna Pharmaceuticals employs 187 staff and has a trailing 12-month revenue of around USD$89.6 million.

How to buy shares in Dicerna Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Dicerna Pharmaceuticals. Find the stock by name or ticker symbol: DRNA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Dicerna Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$22.6, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Dicerna Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Dicerna Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Dicerna Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Dicerna Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$22.6, which is 7.88% up on its pre-crash value of USD$20.82 and 92.34% up on the lowest point reached during the March crash when the shares fell as low as USD$11.75.

If you had bought USD$1,000 worth of Dicerna Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$856.12 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,153.05.

Dicerna Pharmaceuticals share price

Use our graph to track the performance of DRNA stocks over time.

Dicerna Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$22.6
52-week range	USD$11.75 - USD$27.68
50-day moving average	USD$18.7657
200-day moving average	USD$21.0127
Wall St. target price	USD$34.56
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.376

Buy Dicerna Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Dicerna Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Dicerna Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dicerna Pharmaceuticals price performance over time

Historical closes compared with the close of $22.6 from 2020-11-16

1 week (2020-11-18)	-0.57%
1 month (2020-10-23)	16.55%
3 months (2020-08-25)	20.86%
6 months (2020-05-22)	-2.16%

1 year (2019-11-25)	-4.80%
2 years (2018-11-23)	57.16%
3 years (2017-11-24)	135.91%
5 years (2015-11-25)	84.34%

Dicerna Pharmaceuticals financials

Revenue TTM	USD$89.6 million
Gross profit TTM	USD$-85,435,000
Return on assets TTM	-15.16%
Return on equity TTM	-77.42%
Profit margin	-139.27%
Book value	$2.182
Market capitalisation	USD$1.5 billion

TTM: trailing 12 months

Shorting Dicerna Pharmaceuticals shares

There are currently 4.7 million Dicerna Pharmaceuticals shares held short by investors – that's known as Dicerna Pharmaceuticals's "short interest". This figure is 22.3% up from 3.9 million last month.

There are a few different ways that this level of interest in shorting Dicerna Pharmaceuticals shares can be evaluated.

Dicerna Pharmaceuticals's "short interest ratio" (SIR)

Dicerna Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Dicerna Pharmaceuticals shares currently shorted divided by the average quantity of Dicerna Pharmaceuticals shares traded daily (recently around 615197.66839378). Dicerna Pharmaceuticals's SIR currently stands at 7.72. In other words for every 100,000 Dicerna Pharmaceuticals shares traded daily on the market, roughly 7720 shares are currently held short.

However Dicerna Pharmaceuticals's short interest can also be evaluated against the total number of Dicerna Pharmaceuticals shares, or, against the total number of tradable Dicerna Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Dicerna Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Dicerna Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0675% of the tradable shares (for every 100,000 tradable Dicerna Pharmaceuticals shares, roughly 68 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Dicerna Pharmaceuticals.

Find out more about how you can short Dicerna Pharmaceuticals stock.

Dicerna Pharmaceuticals share dividends

We're not expecting Dicerna Pharmaceuticals to pay a dividend over the next 12 months.

Dicerna Pharmaceuticals share price volatility

Over the last 12 months, Dicerna Pharmaceuticals's shares have ranged in value from as little as $11.75 up to $27.68. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dicerna Pharmaceuticals's is 1.46. This would suggest that Dicerna Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Dicerna Pharmaceuticals overview

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Frequently asked questions

• What percentage of Dicerna Pharmaceuticals is owned by insiders or institutions?

  Currently 7.491% of Dicerna Pharmaceuticals shares are held by insiders and 83.074% by institutions.

• How many people work for Dicerna Pharmaceuticals?

  Latest data suggests 187 work at Dicerna Pharmaceuticals.

• When does the fiscal year end for Dicerna Pharmaceuticals?

  Dicerna Pharmaceuticals's fiscal year ends in December.

• Where is Dicerna Pharmaceuticals based?

  Dicerna Pharmaceuticals's address is: 33 Hayden Avenue, Lexington, MA, United States, 02421

• What is Dicerna Pharmaceuticals's ISIN number?

  Dicerna Pharmaceuticals's international securities identification number is: US2530311081

• What is Dicerna Pharmaceuticals's CUSIP number?

  Dicerna Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 253031108